Participated · Series A · Jun 2026

Ilant Health provides end-to-end, clinician-led obesity and cardiometabolic care that combines behavioral therapy, medication (GLP-1 and non-GLP-1), and surgical options within a precision-medicine model that continuously adapts treatment to individual response. The company works directly with employers and health plans to deliver measurable clinical and financial outcomes and to manage both treatment costs and total cost of care. Early results reported by Ilant show members achieve an average 15% weight loss and an average of two additional mentally healthy days per month. Ilant emphasizes data- and analytics-driven care pathways, clinician oversight, and transparent contracting for medications; it has announced direct contracting and transparent pricing through Lilly’s Employer Connect program and is working with Novo Nordisk. The company presents itself as an AI-enabled healthcare services provider that aims to move obesity care from disconnected interventions to a continuous, outcomes-focused service. Ilant has raised over $22 million to date following the $15 million Series A and is partnering with employers and payers to scale its model.

Participated · Series A · Dec 2025

Founded in 2020, Jutro Medical operates a network of technology-enabled primary care clinics supported by a proprietary electronic health record (EHR) and unified operations platform. Its AI agents automate intake, documentation, and other administrative tasks so clinicians can focus on diagnosis and treatment; these agents already handle thousands of patient interactions each month. The company has grown from a single clinic to an integrated operator that added nine clinics in 2024 and plans roughly 20 acquisitions per year to accelerate consolidation of Europe’s fragmented primary care sector. By running clinics on its own software, Jutro identifies workflows ripe for automation, embedding AI directly into day-to-day operations while still giving patients the option of traditional appointments. The business is positioning itself against industry pressures such as clinician shortages and paper-based workflows that slow access to care. To date, Jutro Medical has raised €36 million, including the latest extension, to finance clinic acquisitions, platform enhancements, and expansion into additional European markets. While revenue figures are not disclosed, the company is targeting pan-European scale in a primary care market that exceeds €200 billion annually.

Participated · Series A · Nov 2024

Kyan Health is a Zurich-based provider of an AI-powered enterprise solution that connects employee well-being with organizational measures to drive business impact. Its subscription-based platform centers on Kai, an AI-powered care navigator that connects employees to personalized resources ranging from crisis support to certified coaching and mental health counseling. The platform uses predictive analytics to help companies monitor and reduce risks such as absenteeism, turnover, and presenteeism. Kyan provides confidential, end-to-end encrypted access and shares only aggregated insights with employers to safeguard privacy. Clients named in the article include Hitachi Energy, Hilti, STADA, Deutsche Börse Group, and On. The company raised $16.7M (a $4M seed and a $12.7M Series A), bringing total funding to $18.4M, and plans to use the proceeds to expand operations and development efforts. Kyan was co-founded by Vlad Gheorghiu, Konstantin Struck, and Ignacio Leonhardt. Kyan Health is a Swiss digital health startup that provides end-to-end, fully personalized, evidence-based mental wellbeing and health solutions for employees and their families. The company aims to create a frictionless experience for accessing and engaging with workplace mental health support, spanning employee engagement and awareness, self-improvement and self-care, coaching, and counselling. Incorporated in March 2021, Kyan launched after the founders’ direct experiences with workplace mental health shortcomings. The startup plans to strengthen its network of certified therapists and coaches, modify its app, and scale self-care programs to cover anxiety, depression, and other common workplace mental health challenges. It also intends to build out its skills and coaching offering for corporate clients. Kyan has secured external financing to support these product and network expansions.

Participated · Equity · Oct 2023

Mybacs is described in the article as operating in biotech, health services and pharmaceutical sectors. On 22 October 2023 the company completed a €5.6 million equity financing, reported at roughly $5.99 million. The round listed participation from NaturalX Health Ventures, Wenvest Capital, SevenVentures, Global Founders Capital (GFC), Joyance Partners and G‑Fund. Coverage of the transaction in the cited text focuses on the financing amount and investor roster rather than product detail or operating metrics. The financing represents a capital injection from a mix of investment groups named in the announcement. Mybacs develops highly-dosed synbiotic dietary supplements composed of selected bacterial cultures, prebiotics, vitamins and minerals, tailored to specific customer needs and applications. The company launched Travelbacs in 2018 and later expanded its portfolio with Dailybacs, a subscription synbiotic for daily use for women, men and children. After a successful first financing in August 2019, Mybacs has completed a Seed II round to continue its growth. Participants in the new round include existing investor Global Founders Capital, returning business angels, and San Francisco–based Joyance Partners as the first international investor. The funds will be used to grow the team, develop personalized products and build a dedicated tech platform. Mybacs plans to hire specialists in technology and data and to develop a platform for symptomatic and intelligent data analysis to drive further product personalization and development. mybacs is a B2C biotech startup that develops personalized synbiotic products targeting the human gut microbiome for intestinal health. In February 2019 the company launched the world’s first regionally adapted synbiotics for prevention of travelers' diarrhea, offering 5-day capsule treatments tailored to different geographic pathogenic profiles. Products are available for Africa & the Middle East, Asia, Europe & North America, and Latin America. In the first six months after launch the startup grew greatly and currently sells through its own online shop (mybacs.co), Amazon, BRACK.CH, numerous German and Swiss pharmacies, and plans to sell through airlines. The newly closed seed financing will be used to launch another product line, expand personnel, and increase sales and marketing activities. Long-term plans include expanding the gastrointestinal health product portfolio, introducing a daily-use subscription product line in October, and offering an app to track users' health progress.